Key Insights

Highlights

Success Rate

68% trial completion

Published Results

43 trials with published results (23%)

Research Maturity

76 completed trials (41% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

18.7%

35 terminated out of 187 trials

Success Rate

68.5%

-18.0% vs benchmark

Late-Stage Pipeline

13%

24 trials in Phase 3/4

Results Transparency

57%

43 of 76 completed with results

Key Signals

43 with results68% success35 terminated

Data Visualizations

Phase Distribution

161Total
Not Applicable (18)
Early P 1 (1)
P 1 (42)
P 2 (76)
P 3 (18)
P 4 (6)

Trial Status

Completed76
Terminated35
Recruiting24
Active Not Recruiting21
Unknown17
Withdrawn9

Trial Success Rate

68.5%

Benchmark: 86.5%

Based on 76 completed trials

Clinical Trials (187)

Showing 20 of 20 trials
NCT04467021Not ApplicableActive Not Recruiting

Cancer and Blood Pressure Management, CARISMA Study

NCT05863351Phase 3Active Not RecruitingPrimary

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

NCT07405086Phase 4Recruiting

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

NCT03055013Phase 3Active Not RecruitingPrimary

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

NCT06500455Phase 3Recruiting

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06835972Phase 1RecruitingPrimary

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

NCT05327686Phase 2RecruitingPrimary

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT07043608Phase 2Not Yet Recruiting

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

NCT03647878Active Not Recruiting

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

NCT03284385Phase 2Active Not Recruiting

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

NCT03682289Phase 2Active Not Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

NCT06284564Phase 2Active Not RecruitingPrimary

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

NCT07227415Phase 1Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT04693377Not ApplicableRecruiting

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

NCT03575611Phase 2SuspendedPrimary

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

NCT02298959Phase 1Active Not Recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT07500831Not ApplicableNot Yet Recruiting

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

NCT03786796Phase 2Recruiting

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

NCT07123090Phase 2RecruitingPrimary

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

NCT04788095Not ApplicableActive Not RecruitingPrimary

App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer

Scroll to load more

Research Network

Activity Timeline